Insulin formulations have undergone significant improvements in recent decades. While insulin is a recommended treatment option across the spectrum of treatment for patients with T2DM, unmet clinical needs remain. Three insulin formulations were recently approved in the United States and others are in late-stage development with features that address one or more of these unmet clinical needs.